The pharmacokinetic profile of ceftaroline has not been well characterized in obese adults. The purpose of this study was to evaluate the pharmacokinetics of ceftaroline in 32 healthy adult volunteers aged 18-50 years in the normal, overweight, and obese body size range. Subjects were evenly assigned to 1 of 4 groups based on their body mass index (BMI) and total body weight (TBW) (range 22.1-63.5 kg/m2 and 50.1-179.5 kg, respectively). Subjects in the lower TBW groups were matched by age, sex, race/ethnicity, and serum creatinine to the upper BMI groups. Serial plasma and urine samples were collected over 12 hours following the start of the infusion and concentrations of ceftaroline fosamil (prodrug), ceftaroline, and ceftaroline M-1 (inactive metabolite) were assayed. Noncompartmental and population pharmacokinetic analyses were used to evaluate the data.

 

(후략)